

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Investigation the Effect of Nitrate in Beetroot Powder (Beta Vulgaris) on Glycemic Control and Lipid Parameters in Type 2 Diabetic Patients

#### Protocol summary

##### Study aim

Investigation of the effect of nitrate in Beetroot Powder on glycemic control and lipid parameters in type 2 diabetic patients

##### Design

This study is a clinical practice with control group, parallel groups, blind, and randomized. Individuals are randomly classified (based on hemoglobin concentration of glycoocyte; HbA1C) in a group of Beetroot Powder or placebo supplementation (nitrate-free beet pulp). The sample size for current study is 62 patients with type 2 diabetes.

##### Settings and conduct

In this study, patients with type 2 diabetes who are referred to the Iranian Diabetes Association are selected. Patients will receive supplementation or placebo for 24 weeks. At the end of the twenty-fourth week, anthropometric and blood pressure measurements are again evaluated and blood samples are taken after 12 to 14 hours of fasting. A 24-hour urine sample will be taken at the beginning and end of the study to measure the concentration of nitric oxide, creatinine, and microalbumin intake. Blood samples were taken to determine serum levels of fasting plasma glucose, hemoglobin glycosylated, insulin, serum TG, TC, LDL-c, HDL-c, thyroid tests (TSH, TT4, FT4, FT3, Anti-TPO), liver enzymes (gamma-glutamyltransferase, Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase), Complete Blood Count (CBC). At the end, the mean of the variables in each group was compared during the study period and between the two groups.

##### Participants/Inclusion and exclusion criteria

Adults with type 2 diabetes

##### Intervention groups

Subjects in the intervention group, intake daily supplementation is about 250 mg of nitrate in the form of Beet Pulp. Subjects in the placebo group, will receive free beet pulp powder (less than 10 mg nitrate per day),

and they will receive supplemental and placebo for 24 weeks

##### Main outcome variables

Blood Glucose, Lipid Profile

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180409039246N1**

Registration date: **2018-05-27, 1397/03/06**

Registration timing: **registered\_while\_recruiting**

Last update: **2018-05-27, 1397/03/06**

Update count: **0**

##### Registration date

2018-05-27, 1397/03/06

##### Registrant information

##### Name

Zahra Bahadoran

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2243 2500

##### Email address

z.bahadoran@endocrine.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-05-05, 1397/02/15

##### Expected recruitment end date

2019-03-06, 1397/12/15

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Investigation the Effect of Nitrate in Beetroot Powder (Beta Vulgaris) on Glycemic Control and Lipid Parameters in Type 2 Diabetic Patients

**Public title**

Effect of Beetroot Powder on diabetes treatment

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Non Pregnant and Non Breast Feeding Women

**Exclusion criteria:**

Women of childbearing age without using a safe Contraceptive method Smokers and alcohol consumers Consumers of hormonal medicines Consumers of antioxidant supplements Subjects with Heart, Liver, Lung, Chronic Kidney Disease and Thyroid Disorders Subjects with acute or chronic Inflammatory Diseases Phosphodiesterase 5 inhibitors, Migraine drugs (such as Sumatriptan), Allopurinol, Tri-rings Antidepressants, Antihistamines, Nitrate-containing drugs, Meperidine, and Sedative Medicines Consumers

**Age**

From **18 years** old to **50 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Investigator

**Sample size**

Target sample size: **62**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Random assignment to intervention and control groups

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Given that the supplementation of Nitrate in the form of Beet Pulp in the supplement and the placebo is placed in the same full capsule, it is natural that the investigator and the patient are not aware of the type of supplement received.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

**Street address**

No 24, Parvaneh st., Yemen Blvd., Chamran exp.

**City**

Tehran

**Province**

Tehran

**Postal code**

19395-4763

**Approval date**

2017-05-30, 1396/03/09

**Ethics committee reference number**

IR-SBMU.ENDOCRINE.REC-1395.322

**Health conditions studied****1****Description of health condition studied**

Type 2 diabetes mellitus

**ICD-10 code**

E11

**ICD-10 code description**

Type 2 diabetes mellitus

**Primary outcomes****1****Description**

Blood glucose

**Timepoint**

At baseline of study, 4, 12 and 24 week

**Method of measurement**

Enzymatic colorimetry

**2****Description**

Hemoglobin glycosylated

**Timepoint**

At baseline of study, 4, 12 and 24 week

**Method of measurement**

Enzymatic method

**3****Description**

Triglyceride

**Timepoint**

At baseline of study, 4, 12 and 24 week

**Method of measurement**

Enzymatic colorimetry

## 4

### **Description**

High density lipoprotein

### **Timepoint**

At baseline of study, 4, 12 and 24 week

### **Method of measurement**

Enzymatic colorimetry

## 5

### **Description**

Total cholesterol

### **Timepoint**

At baseline of study, 4, 12 and 24 week

### **Method of measurement**

Enzymatic colorimetry

## **Secondary outcomes**

## 1

### **Description**

Weight

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Scale

## 2

### **Description**

Physical activity

### **Timepoint**

At baseline and end of study

### **Method of measurement**

Physical activity questionnaire

## 3

### **Description**

Dietary intake

### **Timepoint**

At baseline and end of study

### **Method of measurement**

Feed Frequency Questionnaire

## 4

### **Description**

Blood pressure

### **Timepoint**

At baseline and end of study

### **Method of measurement**

Manometer

## 5

### **Description**

Concentration of Alanine Aminotransferase

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Photometry

## 6

### **Description**

Aspartate aminotransferase concentration

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Photometry

## 7

### **Description**

Concentration of alkaline phosphatase

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Photometry

## 8

### **Description**

Gamma glutamyltransferase concentration

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Photometry

## 9

### **Description**

Thyroid Stimulating Hormon

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Electrochemical Luminescence (Laboratory Kit)

## 10

### **Description**

Total thyroxine

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Electrochemical Luminescence (Laboratory Kit)

## 11

### **Description**

Free thyroxine

### **Timepoint**

At baseline of study, 4th,12th and 24th week

### **Method of measurement**

Electrochemical Luminescence (Laboratory Kit)

## 12

### **Description**

Free triiodothyronine

### **Timepoint**

at baseline of study, 4th,12th and 24th week

### **Method of measurement**

Electrochemical Luminescence (Laboratory Kit)

### 13

**Description**

Urinary microalbumin

**Timepoint**

At baseline of study, 4th,12th and 24th week

**Method of measurement**

Immunoturbidometry

### 14

**Description**

Urinary creatinine

**Timepoint**

At baseline of study, 4th,12th and 24th week

**Method of measurement**

Jaffe kinetic method

### 15

**Description**

Nitric Oxide Metabolites

**Timepoint**

at baseline of study, 4th,12th and 24th week

**Method of measurement**

Spectrophotometric method and Grease reaction

### 16

**Description**

Waist circumference

**Timepoint**

At baseline of study, 4th,12th and 24th week

**Method of measurement**

Meter bar

## Intervention groups

### 1

**Description**

Intervention group:250 mg nitrate supplement in beetroot powder

**Category**

Treatment - Other

### 2

**Description**

Control group: free nitrate beetroot powder( nitrate below10 mg)

**Category**

Treatment - Other

## Recruitment centers

### 1

**Recruitment center****Name of recruitment center**

Iran diabetes society

**Full name of responsible person**

asad allah rajab

**Street address**

no.27 , Malakoti street., Patris lomomba street, Tehran, I.R. Iran.

**City**

Tehran

**Province**

Tehran

**Postal code**

14439-14661

**Phone**

+98 21 8824 8124

**Email**

lr.ids1968@yahoo.com

## Sponsors / Funding sources

### 1

**Sponsor****Name of organization / entity**

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Zahra Bahadoran

**Street address**

No.24, Parvaneh St., Yemen Blvd., Chamran Exp.

**City**

Tehran

**Province**

Tehran

**Postal code**

19395-4763

**Phone**

+98 21 2243 2500

**Email**

azizi@erc.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

43

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

### 2

**Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Zahra bahadoran

**Street address**

No.2 , Arabi Ave., Velenjak, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

19839-63113

**Phone**

+98 21 2243 9770

**Email**

Intl\_office@sbmu.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

57

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Zahra Bahadoran

**Position**

Asistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No.24, Parvaneh St., Yemen Blvd., Chamran Exp.

**City**

Tehran

**Province**

Tehran

**Postal code**

19395-4763

**Phone**

+98 22432500

**Email**

zahrabahadoran@yahoo.com

**Person responsible for scientific**

**inquiries**

**Contact**

**Name of organization / entity**

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Zahra Bahadoran

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No.24, Parvaneh St., Yemen Blvd., Chamran Exp.

**City**

Tehran

**Province**

Tehran

**Postal code**

19395-4763

**Phone**

+98 21 2243 2500

**Email**

zahrabahadoran@yahoo.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Zahra Bahadoran

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No.24, Parvaneh St., Yemen Blvd., Chamran Exp.

**City**

Tehran

**Province**

Tehran

**Postal code**

19395-4763

**Phone**

+98 21 2243 2500

**Email**

Zahrabahadoran@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available